

Dimitri Bennett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6409209/publications.pdf>

Version: 2024-02-01

40
papers

1,184
citations

331670

21
h-index

395702

33
g-index

40
all docs

40
docs citations

40
times ranked

1515
citing authors

#	ARTICLE	IF	CITATIONS
1	Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 109-119.	3.5	52
2	Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database. <i>Gastroenterology</i> , 2022, 162, 109-121.e5.	1.3	45
3	Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210741.	3.2	4
4	ISPEâ€œEndorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVIDâ€œ19: Opportunities and Tradeâ€œOffs. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 990-999.	4.7	8
5	Mesenchymal Stem Cell Therapy Awareness, Knowledge, and Use for the Treatment of Fistulizing Crohnâ€œs Disease: An International Survey Among Gastroenterologists and Colorectal Surgeons. <i>Advances in Therapy</i> , 2022, 39, 2761-2777.	2.9	2
6	Machine learning for improving highâ€œdimensional proxy confounder adjustment in healthcare database studies: An overview of the current literature. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 932-943.	1.9	5
7	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. <i>Gut</i> , 2021, 70, 644-653.	12.1	76
8	Aggregate Safety Assessment Planning for the Drug Development Life-Cycle. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 717-732.	1.6	8
9	How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools. <i>BMJ Open</i> , 2021, 11, e043961.	1.9	9
10	Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007â€œ2016. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 619-625.	1.9	89
11	The First National Prevalence Estimation of Gastroparesis in the United States Using a Large-scale Retrospective Database. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 106-106.	2.2	4
12	The utility of <sc>realâ€œworld</sc> evidence for benefitâ€œrisk assessment, communication, and evaluation of pharmaceuticals: Case studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1532-1539.	1.9	9
13	Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. <i>Drugs - Real World Outcomes</i> , 2020, 7, 97-107.	1.6	15
14	Masking in Pragmatic Trials: Who, What, and When to Blind. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 431-436.	1.6	12
15	Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis. <i>Advances in Therapy</i> , 2019, 36, 3503-3518.	2.9	33
16	Systematic review with metaâ€œanalysis: Safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. <i>JGH Open</i> , 2019, 3, 249-260.	1.6	34
17	Masking in Pragmatic Trials: Who, What, and When to Blind. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901984312.	1.6	11
18	Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: Do Algorithms Generate Similar Findings?. <i>Inquiry (United States)</i> , 2019, 56, 004695801988781.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. <i>Diabetology International</i> , 2019, 10, 24-36.	1.4	25
20	Prevalence of anal fistula in the United Kingdom. <i>World Journal of Clinical Cases</i> , 2019, 7, 1795-1804.	0.8	32
21	Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000481.	2.8	23
22	Risk factors for postoperative infection after gastrointestinal surgery among adult patients with inflammatory bowel disease: Findings from a large observational US cohort study. <i>JGH Open</i> , 2018, 2, 182-190.	1.6	12
23	Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 239-241.	4.7	26
24	Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000303.	2.8	11
25	Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. <i>European Journal of Haematology</i> , 2016, 97, 321-330.	2.2	59
26	Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study. <i>Diabetology International</i> , 2016, 7, 375-383.	1.4	4
27	United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. <i>British Journal of Haematology</i> , 2015, 169, 590-594.	2.5	25
28	Thromboembolic Events Among Patients with Hepatitis C Virus Infection and Cirrhosis: A Matched-Cohort Study. <i>Advances in Therapy</i> , 2014, 31, 891-903.	2.9	43
29	Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic Chemotherapy. <i>Drug Safety</i> , 2011, 34, 1151-1160.	3.2	54
30	Prevalence of Diagnosed Adult Immune Thrombocytopenia in the United Kingdom. <i>Advances in Therapy</i> , 2011, 28, 1096-1104.	2.9	33
31	Comorbidities in patients with persistent or chronic immune thrombocytopenia. <i>International Journal of Hematology</i> , 2010, 92, 289-295.	1.6	58
32	Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. <i>Haematologica</i> , 2010, 95, 1167-1175.	3.5	197
33	Predictors of Warfarin Use in Atrial Fibrillation Patients in the Inpatient Setting. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 37-48.	2.2	42
34	Disease Progression, Treatment Effectiveness, and Co-Morbid Burden Among Adult Patients with Primary Immune Thrombocytopenia (ITP): Results From the United Kingdom Registry. <i>Blood</i> , 2009, 114, 4457-4457.	1.4	1
35	Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 43-51.	1.9	22
36	Epidemiology and outcomes in patients with atrial fibrillation in the United States. <i>Heart Rhythm</i> , 2008, 5, 1365-1372.	0.7	65

#	ARTICLE	IF	CITATIONS
37	Thromboembolic Events among Adult Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom General Practice Research Database.. Blood, 2008, 112, 3401-3401.	1.4	3
38	Prevalence Estimates of Adult Chronic Idiopathic Thrombocytopenic Purpura (ITP) in the United States.. Blood, 2007, 110, 3202-3202.	1.4	21
39	The Incidence of Idiopathic Thrombocytopenic Purpura (ITP) among Adults in the United Kingdom's General Practice Research Database (GPRD), 1992-2005.. Blood, 2007, 110, 3209-3209.	1.4	6
40	Risk of Cataracts among Idiopathic Thrombocytopenic Purpura (ITP) Patients in the UK General Practice Research Database (GPRD).. Blood, 2007, 110, 3922-3922.	1.4	2